explore -WSS

explore

author：entertainment 2025-08-19 18:00:52 - browse：57716

Element Biosciences exterior -- biotech coverage from STAT — Element Biosciences exterior Element Biosciences

SAN DIEGO — Companies racing to read the genome accurately, quickly, and affordably have hit a snag recently, with several firms reporting that their growth has slowed, stalled, or reversed. Upstart Element Biosciences is hoping it can succeed despite the challenging market conditions.

The San Diego firm launched a $290,000 sequencer, dubbed Aviti, in March 2022 and now has 150 instruments installed in more than 25 countries, according to a sales update Element shared with STAT. The modest growth comes at a time when some other players are struggling. Singular Genomics announced layoffs of 20% of its workforce earlier this year after the lackluster launch of its own sequencer. And Pacific Biosciences recently laid off nearly 200 employees after reporting disappointing first-quarter sales.

Element still has a long way to go in its bid to rival Illumina, a genomics giant that dominates 80% of the sequencing market and has more than 23,000 instruments in use around the world. That includes the NextSeq 2000, a $335,000 sequencer with a similar output to Aviti. Element is betting its blend of accuracy and a more moderate price point can help it carve out a niche of academic and biopharma customers.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： What PEPFAR has meant on the ground in Ukraine

focus

WSS

Americans' trust in science, scientist continues decline: Report

When prostate cancer spreads, where it goes matters

After sickle

Leukemia patients are helped by Syndax's new type of therapy

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

hotspot

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

focus

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Microsoft's Peter Lee says ChatGPT shouldn't be used for initial diagnosis

Activists slam private health insurers over coverage restrictions

Leukemia patients are helped by Syndax's new type of therapy

Apple is now the first public company to be valued at $3 trillion

Pfizer plans to depart BIO

Hepatitis C has a cure — but many Americans still lack access to it

SCOTUS to consider access to abortion pill mifepristone

Alkermes shareholders re

The woman behind the Dana Farber

knowledge

Glen Campbell's doctor discusses his public struggle with Alzheimer's

Helping hospitals and community health centers plan for resilience

Wearables generate powerful data but its not useful to doctors, yet

Criminal prosecution for violating HIPAA: an emerging threat

Supreme Court wrestles with OxyContin maker's bankruptcy deal

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

explore

focus

leisure time

hotspot